InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

Author:

Orlow IreneORCID,Sadeghi Keimya D.,Edmiston Sharon N.,Kenney Jessica M.,Lezcano Cecilia,Wilmott James S.,Cust Anne E.,Scolyer Richard A.ORCID,Mann Graham J.,Lee Tim K.,Burke Hazel,Jakrot Valerie,Shang Ping,Ferguson Peter M.ORCID,Boyce Tawny W.,Ko Jennifer S.,Ngo Peter,Funchain Pauline,Rees Judy R.,O’Connell Kelli,Hao Honglin,Parrish Eloise,Conway Kathleen,Googe Paul B.,Ollila David W.,Moschos Stergios J.,Hernando Eva,Hanniford Douglas,Argibay Diana,Amos Christopher I.,Lee Jeffrey E.,Osman Iman,Luo Li,Kuan Pei-FenORCID,Aurora Arshi,Gould Rothberg Bonnie E.,Bosenberg Marcus W.,Gerstenblith Meg R.,Thompson Cheryl,Bogner Paul N.,Gorlov Ivan P.,Holmen Sheri L.,Brunsgaard Elise K.,Saenger Yvonne M.,Shen Ronglai,Seshan Venkatraman,Nagore Eduardo,Ernstoff Marc S.,Busam Klaus J.,Begg Colin B.,Thomas Nancy E.,Berwick Marianne,

Abstract

Introduction We are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of generally small-sized pigmented tumor samples including primary melanomas of at least 1.05mm from AJTCC TNM stage IIA-IIID patients. We also evaluated tissue-derived predictors of extracted nucleic acids’ quality and success in downstream testing. This ongoing study will target 1,000 melanomas within the international InterMEL consortium. Methods Following a pre-established protocol, participating centers ship formalin-fixed paraffin embedded (FFPE) tissue sections to Memorial Sloan Kettering Cancer Center for the centralized handling, dermatopathology review and histology-guided coextraction of RNA and DNA. Samples are distributed for evaluation of somatic mutations using next gen sequencing (NGS) with the MSK-IMPACTTM assay, methylation-profiling (Infinium MethylationEPIC arrays), and miRNA expression (Nanostring nCounter Human v3 miRNA Expression Assay). Results Sufficient material was obtained for screening of miRNA expression in 683/685 (99%) eligible melanomas, methylation in 467 (68%), and somatic mutations in 560 (82%). In 446/685 (65%) cases, aliquots of RNA/DNA were sufficient for testing with all three platforms. Among samples evaluated by the time of this analysis, the mean NGS coverage was 249x, 59 (18.6%) samples had coverage below 100x, and 41/414 (10%) failed methylation QC due to low intensity probes or insufficient Meta-Mixed Interquartile (BMIQ)- and single sample (ss)- Noob normalizations. Six of 683 RNAs (1%) failed Nanostring QC due to the low proportion of probes above the minimum threshold. Age of the FFPE tissue blocks (p<0.001) and time elapsed from sectioning to co-extraction (p = 0.002) were associated with methylation screening failures. Melanin reduced the ability to amplify fragments of 200bp or greater (absent/lightly pigmented vs heavily pigmented, p<0.003). Conversely, heavily pigmented tumors rendered greater amounts of RNA (p<0.001), and of RNA above 200 nucleotides (p<0.001). Conclusion Our experience with many archival tissues demonstrates that with careful management of tissue processing and quality control it is possible to conduct multi-omic studies in a complex multi-institutional setting for investigations involving minute quantities of FFPE tumors, as in studies of early-stage melanoma. The study describes, for the first time, the optimal strategy for obtaining archival and limited tumor tissue, the characteristics of the nucleic acids co-extracted from a unique cell lysate, and success rate in downstream applications. In addition, our findings provide an estimate of the anticipated attrition that will guide other large multicenter research and consortia.

Funder

Foundation for the National Institutes of Health

Australian Research Council

Faculty of Medicine and Health, University of Sydney

the Huntsman Foundation

Char and Chuck Fowler Family Foundation

Cleveland Foundation

Roswell Park Alliance Foundation, Roswell Park Cancer Institute

University of Texas MD Anderson Cancer Center Miriam and Jim Mulva Research Fund

The McCarthy Skin Cancer Research Fund

The Marit Peterson Fund for Melanoma Research

The Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair

Robert E. Leet and Clara Guthrie Patterson Trust

National Institute of General Medical Sciences

Cycle for Survival

Marie-Josée and Henry R. Kravis Center for Molecular Oncology

The Ainsworth Foundation

ClearBridge Foundation

The Cameron Family

Melanoma Institute Australia

Royal Prince Alfred Hospital

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. Cancer statistics, 2022.;RL Siegel;CA Cancer J Clin.,2022

2. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer Statistics Review Bethesda, MD: National Cancer Institute; 1975–2010 [updated April 2013. Available from: http://seer.cancer.gov/csr/1975_2010/].

3. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database;SJ Soong;Ann Surg Oncol,2010

4. Malignant melanoma in the elderly: different regional disease and poorer prognosis;JB Macdonald;J Cancer,2011

5. Malignant melanoma: clinical variants and prognostic indicators;RM MacKie;Clin Exp Dermatol,2000

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3